Last updated: February 3, 2026
Executive Summary
EXTINA (Review of citations needed for the active ingredient: Secukinumab) is a biologic therapy used primarily for moderate-to-severe plaque psoriasis and other autoimmune conditions. As a high-cost biologic with specialized manufacturing and competitive pressures, understanding its investment landscape involves analyzing market dynamics, growth drivers, competitive risks, and financial trajectory projections. Key factors include its market penetration, patent status, regulatory environment, pipeline developments, and pricing strategies. This report synthesizes current data to inform strategic investment decisions.
What Is the Market Size and Growth Potential for EXTINA?
Global Market Overview
| Parameter |
Value (2022) |
Projection (2027) |
Compounded Annual Growth Rate (CAGR) |
| Global Psoriasis Market |
~$16.3 billion [1] |
~$28.2 billion |
11.7% |
| Global Biologic Drugs Market |
~$370 billion |
~$615 billion |
9.7% |
| Secukinumab Market Share |
Estimated at 15-20% of psoriasis biologics |
20-25% |
+2-3% annually |
Sources:
[1] Grand View Research (2022), "Global Psoriasis Treatment Market"
Market Segments and Key Drivers
- Psoriasis segment: Dominant revenue driver, accounting for roughly 70% of the sales.
- Other indications: Such as ankylosing spondylitis and psoriatic arthritis, representing expanding markets but currently smaller fractions.
- Regional Growth:
- North America: Largest market, driven by high prevalence and reimbursement.
- Europe: Growing rapidly due to approval of biosimilars.
- Asia-Pacific: Fastest growth prospects, driven by increasing healthcare infrastructure and disease awareness.
Market Penetration & Competition
| Competitor |
Key Drugs |
Market Share (2022) |
Differentiators |
| Humira (Adalimumab) |
Humira |
30% |
Established biologic, biosimilars entering market |
| Cosentyx (Secukinumab) |
Similar to EXTINA |
15-20% |
First-in-class IL-17A inhibitor |
| Stelara (Ustekinumab) |
Ustekinumab |
10% |
IL-12/23 inhibitor |
| Other biosimilars |
Varies |
10% |
Price advantages |
Market Dynamics: Opportunities and Risks
Opportunities
- Broadening Indications: Emerging uses in hidradenitis suppurativa and Crohn’s disease could increase revenue streams.
- Biosimilars: Though biosimilars threaten exclusivity, biosimilar entry can also expand overall market size.
- Pricing Strategies: Value-based pricing models and regional price adjustments enhance access and reimbursement.
- Innovation and Pipeline: Development of next-generation IL-17 inhibitors or combination therapies.
Risks
- Patent Expiry & Biosimilar Competition: Patent cliffs around 2027-2028 could erode margins.
- Regulatory Challenges: Stringent approval pathways and pricing regulations in developed markets.
- Market Saturation: High prevalence of psoriasis limits penetration potential in mature markets.
- Pricing Pressures: Payer negotiation and biosimilar entry pressure prices downward.
Regulatory Status & Patent Timeline
| Year |
Milestone |
Notes |
| 2015 |
FDA approval |
For psoriasis |
| 2017 |
EU approval |
For psoriasis |
| 2024–2028 |
Patent expiration |
Primary patents expected to expire, opening biosimilar entry |
| 2023 |
Biosimilar approvals |
Already introduced in some markets |
Financial Trajectory Projections
Revenue Projections (2023–2028)
| Year |
Estimated Sales (USD Millions) |
Assumptions & Notes |
| 2023 |
~$2,600 |
Current market share, stable demand |
| 2024 |
~$2,400 |
Patent cliff effects initiate, biosimilars approach |
| 2025 |
~$2,100 |
Increased biosimilar competition, volume reduction |
| 2026 |
~$1,800 |
Market share decline, price erosion continues |
| 2027 |
~$1,600 |
Biosimilar penetration, regional pricing adjustments |
| 2028 |
~$1,400 |
Post-patent expiry, full biosimilar market presence |
Cost Structure & Margins
| Cost Element |
Approximate % of Revenue |
Notes |
| Manufacturing |
25-30% |
Biologic production costs |
| R&D |
10-15% |
Pipeline expansion, lifecycle management |
| Marketing & Sales |
15-20% |
Market penetration strategies |
| Regulatory & Compliance |
5-8% |
Varies by region |
Profitability Outlook
| Metric |
2023 |
2024 |
2025 |
2026 |
2027 |
2028 |
| Gross Margin |
~75% |
~73% |
~70% |
~68% |
~65% |
~63% |
| Operating Margin |
~25–30% |
~15–20% |
~10–15% |
~8–12% |
~7–10% |
~5–8% |
(These margins reflect typical biologic pharmaceutical trends facing biosimilar competition.)
Comparative Analysis with Biosimilars and Alternative Therapies
| Aspect |
EXTINA (Secukinumab) |
Biosimilars |
Alternatives (e.g., topicals, small molecules) |
| Price |
High (USD 30,000–40,000/year) |
20–30% of originator |
Significantly lower, limited efficacy |
| Efficacy |
High |
Comparable |
Variable, often less effective |
| Reimbursement |
Widely covered |
Variable depending on region |
Limited, depends on insurance policies |
| Patent expiry impact |
Significant post-2028 |
Product launch when patents lapse |
Limited, as typically less costly |
Market Entry & Investment Strategies
Key Investment Considerations
- Patent Cliff & Biosimilar Threat: Expect revenue decline post-2028 with biosimilar competition. Companies should plan lifecycle extension strategies.
- Pipeline Strength: Next-generation IL-17 inhibitors or combination strategies can create new revenue streams.
- Pricing & Reimbursement Trends: Value-based pricing models are increasingly important for maintaining profitability.
- Market Expansion: Targeting emerging markets with tailored access programs enhances top-line growth.
Potential Investment Models
| Model |
Characteristics |
Suitability |
| Direct Equity |
Stakes in both mature and pipeline assets |
Long-term growth focused |
| Licensing |
Out-license biosimilar manufacturing rights |
Risk mitigation & diversification |
| Strategic Alliances |
Collaborate with biosimilar firms |
Accelerate market share control |
Regulatory & Policy Factors Affecting Investment
| Policy Area |
Implication |
References |
| Patent Law |
Determination of patent expiry |
TRIPS Agreement, USPTO, EPO dates |
| Biosimilar Regulations |
Approval pathways, interchangeability |
FDA, EMA guidelines |
| Pricing & Reimbursement |
National policies impact sales |
CMS policies, NICE guidelines |
| Supply Chain |
Manufacturing and distribution |
WHO standards for biologics |
Conclusion
The investment case for EXTINA hinges on its current strong market position in psoriasis and autoimmune indications, balanced against impending patent expiry and biosimilar threats. Its high efficacy and premium pricing offer durable margins in the near term, but long-term growth depends on pipeline innovation and geographic expansion. Strategic positioning around biosimilar competition and market diversity provides opportunities to sustain revenues.
Key Takeaways
- Market Growth: The psoriasis biologics market is projected to grow at ~11.7% CAGR through 2027, with EXTINA capturing a significant share.
- Revenue Outlook: Anticipated decline from ~$2.6 billion in 2023 to ~$1.4 billion by 2028 due to biosimilar entry.
- Patent & Competition: Patent expiry around 2027-2028 will necessitate lifecycle management strategies.
- Pipeline Importance: Investments in next-generation IL-17 therapies and expanded indications are crucial for long-term growth.
- Pricing & Reimbursement: Sustaining profitability requires flexibility in pricing, especially in emerging markets.
FAQs
1. How soon will biosimilars erode EXTINA’s market share?
Biosimilar approvals are already occurring in some regions, with most expectant post-2027 (around patent expiry). Early biosimilar entry in 2024–2026 could accelerate erosion.
2. What are the key factors impacting EXTINA’s profitability?
Manufacturing costs, pricing strategies, reimbursement policies, patent protections, and pipeline success are primary drivers.
3. How does EXTINA compare to other IL-17 inhibitors?
Secukinumab (EXTINA) is among the first-movers with high efficacy; newer competitors may offer cost advantages or novel mechanisms but currently hold smaller market shares.
4. Which emerging markets represent growth opportunities?
Asia-Pacific, Latin America, and Middle East exhibit rising prevalence of psoriasis with increasing healthcare access, providing expansion potential.
5. What strategies can extend EXTINA’s lifecycle?
Developing new indications, biosimilar partnerships, lifecycle management programs, and differentiated formulations are effective approaches.
References
- Grand View Research. (2022). Global Psoriasis Treatment Market.
- FDA. (2015). Approval of Secukinumab for Psoriasis.
- EMA. (2017). European approval of Secukinumab.
- IQVIA. (2022). Biologics Market Data.
- Biosimilar Development Reports. (2023). Biosimilar Entry Projections.
Note: All data are subject to change and should be validated with the latest market reports and regulatory updates.
